ArticleBritish journal of cancer2004
Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications.Aging and disease · 2020Review
- Electrotaxis of Glioblastoma and Medulloblastoma Spheroidal Aggregates.Scientific reports · 2019Article
- Immunotherapies for malignant glioma.Oncogene · 2018Review
- CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.Oncology letters · 2017Article
- Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.Journal of cellular biochemistry · 2017Review
- Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.Cancer research · 2014Article
- Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.Pharmacogenomics and personalized medicine · 2014Review
- Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.ACS chemical biology · 2013Article
- Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.BMC cancer · 2013Article
- Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.Investigational new drugs · 2012Article
- Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.Neoplasia (New York, N.Y.) · 2012Article
- Study of drug function based on similarity of pathway fingerprint.Protein & cell · 2012Article
- Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Review
- Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model.Molecular cancer · 2010Article
- Resistance to Trastuzumab in Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics.Brain pathology (Zurich, Switzerland) · 2009Article
- Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy.Cellular and molecular neurobiology · 2009Article
- Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Review
- Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.Journal of neuro-oncology · 2007Article
- Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours.British journal of cancer · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth. Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not (U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin). Human epithelial receptor type 2/neu expression was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.